The use of TNF-α blocking agents in rheumatoid arthritis: an update

Bibliography

• KIRWAN J: Links between radiological change, disability, and pathology in rheumatoid arthritis. J. Rheumatol. (2001) 28:881-886.
   PubMed Web of Science ®Google Scholar
• BROWN AK, QUINN MA, KARIM Z et al.: Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug – induced clinical remission. Arthritis Rheum. (2006) 54:3761-3773.
   PubMed Web of Science ®Google Scholar
• CHOY HS, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. (1996) 14:397-340.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER JM: Inhibition of the production and effects of interleukin-1 and TNF-α in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151-160.
   PubMed Web of Science ®Google Scholar
• MAINI RN, ELLIOTT MJ, BRENNAN F et al.: Monoclonal anti-TNF-α antibody as a probe of pathogenesis and therapy of rheumatoid arthritis. Immunol. Rev. (1995) 144:195-223.
   PubMed Web of Science ®Google Scholar
• KOLLIAS G, DOUNI E, KASSIOTIS G et al.: On the role of TNF and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. (1999) 169:175-194.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Discovery of TNF-α as a therapeutic target in rheumatoid arthritis. Preclinical and clinical studies. Joint Bone Spine (2002) 69:12-18.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, WENDLING D: The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. (2004) 5(3):581-594.
   PubMed Web of Science ®Google Scholar
• PALEOLOG E: The therapeutic potential of TNF-α blockade in rheumatoid arthritis. Expert Opin. Invest. Drugs (2003) 12:1087-1095.
   PubMed Web of Science ®Google Scholar
• MAINI RN, TAYLOR PC, PALEOLOG E et al.: Antitumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58 (Suppl. I):I56-I60.
   PubMed Web of Science ®Google Scholar
• MARKHAM A, LAMB HM: Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341-1359.
   PubMed Web of Science ®Google Scholar
• MACHOLD KP, SMOLEN JS: Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease. Expert Opin. Biol. Ther. (2003) 3:351-360.
   PubMed Web of Science ®Google Scholar
• CDP571: Anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade. Drugs R&D (2003) 4:174-178.
   Google Scholar
• ETANERCEPT: Soluble TNF receptor, TNF receptor fusion protein, TNF-R-Fc, TNR 001, Enbrel. Drugs R&D (1999) 1:258-261.
   Google Scholar
• RAU R, SANDER O, VAN RIEL P et al.: Intravenous human recombinant TNF receptor p55 IgG1 fusion protein Ro 45-2081 (lenercept): a double-blind, placebo-controlled dose-finding study in rheumatoid arthritis. J. Rheumatol. (2003) 30:680-690.
   PubMed Web of Science ®Google Scholar
• ROSE-JOHN S, SCHOOLTINK H: CDP-870. Curr. Opin. Investig. Drugs (2003) 4:588-592.
   PubMedGoogle Scholar
• DARLINGTON C: PEG-sTNF-RI. Curr. Opin. Investig. Drugs (2003) 4:583-587.
   PubMedGoogle Scholar
• KAUSHIK VV, MOOTS RJ: CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin. Biol. Ther. (2005) 5(4):601-606.
   PubMed Web of Science ®Google Scholar
• PAULUS H, EGGER M, WARD J et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on findings in patients treated with placebo. Arthritis Rheum. (1990) 33:477-484.
   PubMed Web of Science ®Google Scholar
• FELSON D, ANDERSON J, BOERS M et al.: American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
   PubMed Web of Science ®Google Scholar
• VAN GESTEL AM, PREVOO ML, VAN'T HOF MA et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the prelimianry Amercian College of Rheumatology and the World Health Organization/International Leaugue Against Rheumatism Criteria. Arthritis Rheum. (1996) 39:34-40.
   PubMed Web of Science ®Google Scholar
• PREVOO MLL, VAN'T HOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight joint counts. Arthritis Rheum. (1995) 38:44-48.
   PubMed Web of Science ®Google Scholar
• SIDDIQUINI MAS, SCOTT LJ: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs (2005) 65(15):2179-2208.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN RF, GULLSTRÓM E, KLARESKOG L: Feasibility of 1 h infliximab infusions. Ann. Rheum. Dis. (2005) 64:654.
   PubMed Web of Science ®Google Scholar
• BUCH MH, BRYER D, LINDSAY S et al.: Shortening infusion times for infliximab administration. Rheumatology (2006) 45:485-486.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum. (1993) 36:1681-1690.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to TNF-α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-TNF-α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552-1563.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, STCLAIR EW, MCCUNE WJ et al.: Chimeric anti-TNF-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27:841-580.
   PubMed Web of Science ®Google Scholar
• MAINI RN, STCLAIR EW, BREEDVELD FC et al.; for the ATTRACT study group: Infliximab (chimeric anti-TNF-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomittant methotrexate: a randomised Phase III trial. Lancet (1999) 354:1932-1939.
   PubMed Web of Science ®Google Scholar
• LIPSKY P, VAN DER HEIJDE DM, ST CLAIR EW et al.: For the ATTRACT study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1594-1602.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Sustained imporvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. (2004) 50(4):1051-1065.
   PubMed Web of Science ®Google Scholar
• GELETKA RC, ST CLAIR WE: Infliximab for the treatment of early rheumatoid arthritis. Expert Opin. Biol. Ther. (2005) 5(3):405-417.
   PubMed Web of Science ®Google Scholar
• ST CLAIR WE, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Artrhitis Rheum. (2004) 50(11):3432-3443.
   PubMed Web of Science ®Google Scholar
• QUINN MA, CONAGHAN PG, O'CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2005) 52(1):27-35.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC, STEUER A, GRUBER J et al.: Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. (2006) 54(1):47-53.
   PubMed Web of Science ®Google Scholar
• GARRISON L, MCDONNEL ND: Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(Suppl. I):I65-I69.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant TNF receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
   PubMed Web of Science ®Google Scholar
• SPENCER-GREEN G: Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. (2000) 59(Suppl. I):I46-I49.
   Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human TNF receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1999) 130:478-486.
   PubMed Web of Science ®Google Scholar
• BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1450.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, FLEISCHMANN RM et al.: Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J. Rheumatol. (2005) 32:1232-1242.
   PubMed Web of Science ®Google Scholar
• KLARESKOG L, VAN DER HEIJDE DM, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363(9410):675-681.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE DM, KLARESKOG L, RODRIGUEZ-VALVERDE V et al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. (2006) 54(4):1063-1074.
   PubMedGoogle Scholar
• VAN RIEL PLCM, TAGGART AJ, SANY J et al.: Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann. Rheum. Dis. (2006) 65:1478-1483.
   PubMed Web of Science ®Google Scholar
• MORELAND L, WEINBLATT M, KEYSTONE EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. (2006) 33(5):854-861.
   PubMed Web of Science ®Google Scholar
• KEMPENI J: Preliminary results of early clinical trials with the fully human anti-TNF-α monoclonal antibody D2E7. Ann. Rheum. Dis. (1999) 58(Suppl. I):I70-I72.
   PubMed Web of Science ®Google Scholar
• KEMPENI J: Update on D2E7: a fully human antitumour necrosis factor-α monoclonal antibody. Ann. Rheum. Dis. (2000) 59(Suppl. I):I44-I45.
   PubMedGoogle Scholar
• DEN BROEDER A, VAN DE PUTTE LBA, RAU R et al.: A single dose, placebo-controlled study of the fully human anti-TNF-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:2288-2298.
   PubMed Web of Science ®Google Scholar
• DEN BROEDER AA, JOOSTEN LAB, SAXNE T et al.: Long-term anti-TNF-α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311-318.
   PubMed Web of Science ®Google Scholar
• BARRERA P, VAN DER MAAS A, VAN EDE AE et al.: Drug survival, efficacy and toxicity of monotherapy with a fully human anti-TNF-α antibody compared with methotexate in long standing rheumatoid arthritis. Rheumatology (2002) 41:430-439.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomittant methotrexate. The ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
   PubMed Web of Science ®Google Scholar
• FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti-TNF-α monoclonal antibody, and concomittant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J. Rheumatol. (2003) 30:2563-2571.
   PubMed Web of Science ®Google Scholar
• BREEDVLED FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study. A multi-centre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. (2006) 54(1):26-37.
   PubMedGoogle Scholar
• MARIETTE X, MALAISE MG, RAINE F et al.: Adalimumab is effective and safe with traditional concomitant DMARDs in treating rheumatoid arthritis in real life clinical practice: a full set analysis of the ReAct trial. Ann. Rheum. Dis. (2006) 65(Suppl. II):330.
   Google Scholar
• WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. (2002) 29(Suppl. 65):33-68.
   Web of Science ®Google Scholar
• ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and anti-TNF-α therapy. Arthritis Rheum. (2003) 48:3013-3022.
   PubMed Web of Science ®Google Scholar
• RYCHLY DJ, DIPIRO JT: Infections associated with TNF-α antagonists. Pharmacotheraphy (2005) 25:1181-1192.
   PubMed Web of Science ®Google Scholar
• MOHAN VP, SCANGA CA, YU K et al.: Effects of TNF-α on the immune response in chronic persistent tuberculosis: a possible role for limiting pathology. Infect. Immunol. (2001) 69:1847-1855.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a TNF-α – neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
   PubMed Web of Science ®Google Scholar
• WALLIS RS, BRODER MS, WONG JY et al.: Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin. Infect. Dis. (2004) 38:1261-1265.
   PubMed Web of Science ®Google Scholar
• GOMEZ-REINO JJ, CARMONA L, VALVERDE VR et al.: On behalf of the BIOBADASER group. Treatment of rheumatoid arthritis with TNF inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum. (2003) 48:2122-2127.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BRANDT L et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with TNF antagonists in Sweden. Arthritis Rheum. (2005) 52:1986-1992.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K, ANDERSON J et al.: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. (2004) 50:372-379.
   PubMed Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY, CENTER FOR DISEASE CONTROL AND PREVENTION: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. (2000) 161(Suppl. ):S221-S247.
   PubMed Web of Science ®Google Scholar
• SALMON-CERON D, GROUP RATIO, AFSSAPS: Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann. Med. Intern. (2002) 153:429-431.
   PubMedGoogle Scholar
• KENT JD, PANGAN AL, FITZPATRICK SB: Analysis of the US postmarketing safety of adalimumab (HUMIRA) in patients with rheumatoid arthritis during the first 2 years after approval. Arthritis Rheum. (2005) 52(Suppl.):S548.
   PubMedGoogle Scholar
• KROESEN S, WIDMER AF, TYNDALL A et al.: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (2003) 42:617-621.
   PubMed Web of Science ®Google Scholar
• LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with TNF-α antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46:2565-2570.
   PubMed Web of Science ®Google Scholar
• SLIFMAN NR, GERSHON SK, LEE JH et al.: Listeria monocytogenes infection as a complication of treatment with TNF-α-neutralizing agents. Arthritis Rheum. (2003) 48:319-324.
   PubMed Web of Science ®Google Scholar
• BONGARTZ T, SUTTON AJ, SWEETING MJ et al.: Anti-TNF antibody in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295(19):2275-2285.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occuring during anti-TNF-α therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862-2869.
   PubMed Web of Science ®Google Scholar
• ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating and neurologic events reported in association with TNF-α antagonism. By what mechanisms could TNF-α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis. Arthritis Rheum. (2001) 44:1977-1983.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, PERTUISET E, MARTIN A et al.: Association of rheumatoid arthritis with multiple sclerosis. Report of 14 cases and discussion of its significance. J. Rheumatol. (2006) 33:1027-1029.
   PubMed Web of Science ®Google Scholar
• BENSOUDA-GRIMALDI L, MULLEMAN D, VALAT JP et al.: Adalimumab-associated multiple sclerosis. J. Rheumatol. (2007) 34:229.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E: Dr Toussirot replies. J. Rheumatol. (2007) 34:240.
   Web of Science ®Google Scholar
• JARAND J, ZOCHODONE DW, MARTIN LO, VOLL C: Neurological complications of infliximab. J. Rheumatol. (2006) 33:1018-1020.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with TNF antagonists. Ann. Rheum. Dis. (2005) 64:421-1426.
   Google Scholar
• BROWN SL, GREENE MH, GERSHON SK et al.: TNF antagonist therapy and lymphoma development. Twenty-six cases reported to the food and drug administration. Arthritis Rheum. (2002) 46:3151-3158.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum. (2004) 50(6):1740-1751.
   PubMed Web of Science ®Google Scholar
• GEBOREK P, BLADSTROM A, TURESSON C et al.: TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. (2005) 64(5):699-703.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to TNF antagonists. Ann. Rheum. Dis. (2005) 64:1414-1420.
   PubMed Web of Science ®Google Scholar
• SHAKOOR N, MICHALSKA M, HARRIS CA et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579-580.
   PubMed Web of Science ®Google Scholar
• DE BANDT M, VITECOQ O, DESCAMPS V et al.: Anti-TNF-α induced systemic lupus syndrome. Clin. Rheumatol. (2003) 22:56-61.
   PubMed Web of Science ®Google Scholar
• CHARLES PJ, SMEENK RJ, DE JONG J et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF-α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43:2383-2390.
   PubMed Web of Science ®Google Scholar
• DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. (2003) 48:1015-1023.
   PubMedGoogle Scholar
• FLENDRIE M, CREEMERS MCW, WELSING PMJ et al.: The influence of previous and concomittant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (2005) 44:472-478.
   PubMed Web of Science ®Google Scholar
• CHUNG ES, PACKER M, LO KH et al.: Randomized, double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to TNF-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133-3140.
   PubMed Web of Science ®Google Scholar
• KWON HJ, COTE TR, CUFFE MS et al.: Case reports of heart failure after therapy with a TNF antagonist. Ann. Intern. Med. (2003) 138:807-811.
   PubMed Web of Science ®Google Scholar
• FLENDRIE M, VISSERS WH, CREEMERS MC et al.: Dermatological conditions during TNF-α blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. (2005) 7(3):R666-R676.
   PubMed Web of Science ®Google Scholar
• CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. (2004) 63(Suppl. 2):II18-II24.
   PubMed Web of Science ®Google Scholar
• WENDLING D, AUGÉ B, BETTINGER D et al.: Reactivation of a latent precoce mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. (2005) 64:788-789.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, WENDLING D: Bacillus Calmette-GuÉrin vaccination in a patient treated with infliximab. J. Rheumatol. (2005) 32:2500-2501.
   PubMed Web of Science ®Google Scholar
• OSTOR AJ, CRISP AJ, SOMERVILLE MF et al.: Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ (2004) 329:1266.
   PubMed Web of Science ®Google Scholar
• KATZ JA, ANTONI C, KEEMAN GF et al.: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis. Am. J. Gatsroenterol. (2004) 99(12):2385-2392.
   PubMed Web of Science ®Google Scholar
• HYRICH KL, SYMMONS DPM, WATSON KD et al.: Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum. (2006) 54(8):2701-2702.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, BREEDVELD FC, BURMESTER GR et al.: Consensus statement on the initiation and continuation of TNF blocking therapies in rheumatoid artrihitis. Ann. Rheum. Dis. (2000) 59:504-505.
   PubMed Web of Science ®Google Scholar
• GOEKOOP-RUITERMAN YPM, VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study). Arthritis Rheum. (2005) 52(11):3381-3390.
   PubMed Web of Science ®Google Scholar
• DEIGHTON CM, GEORGE E, KIELY PDW et al.: Updating the Bristish Society for Rheumatology guidelines for antitumour necrosis factor therapy in adult rheumatoid arthritis. Rheumatology (2006) 45:649-652.
   PubMed Web of Science ®Google Scholar
• FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheulmatic diseases. Ann. Rheum. Dis. (2006) 65(Suppl. III):III2-III15.
   PubMed Web of Science ®Google Scholar
• FAUTREL B, CONSTANTIN A, MOREL J et al.: Recommendations of the French Society for Rheumatology. TNF-α antagonist therapy in rheumatoid arthritis. Joint Bone Spine (2006) 73:433-441.
   PubMed Web of Science ®Google Scholar
• PERDRIGER A, MARIETTE X, KUNTZ JL et al.: Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J. Rheumatol. (2006) 33:865-869.
   PubMed Web of Science ®Google Scholar
• COMBE B, CODREANU C, FIOCCO U et al.: Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalzine: a double-blind comparison. Ann. Rheum. Dis. (2006) 65:1357-1362.
   PubMed Web of Science ®Google Scholar
• HARAOUI B: Is there a rationale for switching from one anti-TNF agent to another? J. Rheumatol. (2004) 31:1021-1022.
   PubMed Web of Science ®Google Scholar
• BUCH MH, EMERY P: Nonresponse to TNF antagonists – is there any point in retreatment? Nat. Clin. Pract. Rheumatol. (2006) 2:288-289.
   PubMedGoogle Scholar
• MUGNIER B, BALANDRAUD N, DARQUE A et al.: Polymorphism at position-308 of the TNF-α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1849-1852.
   PubMed Web of Science ®Google Scholar
• JOBANPUTRA P, BARTON P, BRYAN S et al.: The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6:1-110.
   PubMedGoogle Scholar
• KOBELT G, JÓNSSON L, YOUNG A et al.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and United-Kingdom based on the ATTRACT study. Rheumatology (2003) 42:326-335.
   PubMed Web of Science ®Google Scholar